A Review on Impurity Profiling In Pharmaceutical Substances
DOI:
https://doi.org/10.22270/ajprd.v12i5.1477Abstract
The term "impurity profiling" describes a group of analytical techniques aimed at detecting, identifying, and quantifying residual solvents and organic and inorganic impurities in bulk medications and pharmaceutical formulations. This is the main objective of contemporary drug analysis since it is the most effective method of characterizing the stability and quality of pharmaceutical formulations and bulk drugs. To monitor them, certain analytical methods have to be developed. Even in cases where synthesis, formulation, or production procedures are improved, new purities may emerge from changes made to them. The International Conference on Harmonization (ICH), the US Food and Drug Administration (FDA), and other regulatory organizations are closely monitoring the identification of contaminants in Active Pharmaceutical Ingredients (APIs) and the requirements for their purity. In addition to degraded end products obtained during manufacture, pharmaceutical goods may contain impurities from a range of sources, such as ligands, heavy metals (HMs), catalysts, reagents, and other components like filter aids and similar compounds. The permissible quantities of pollutants found in APIs or formulations are progressively being limited by a number of pharmacopoeias, including the American, British, and Indian pharmacopoeias. Pharmaceutical contaminants are separated and analyzedby employingvarious techniques, that includes infrared spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, ultracold extraction column chromatography, and ultraviolet spectrometry. For impurity profiling, this is the hyphenated method that is most frequently employed.
Downloads
References
Nagpal S., A. Upadhyay, T. R. Bhardwaj and A. Thakkar , A Review on Need and Importance of Impurity Profiling , ISFAL, I. S. F. College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga 142 001,(2011),Punjab, India:62-70.
Palve R., Gaikwad A. , Mandale K. , Pawar R., A Review of Impurity Profile in Pharmaceutical Substances , Loknete Shree DadapatilPharate College of Pharmacy, MandavganPharata, Pune. Maharashtra,(2018), India.:201-205.
Venkatesan P., and Valliappan K. , Impurity Profiling: Theory and Practice , Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalainagar, (2014) :254-269.
Bari S.B., Kadam B.R., Jaiswal Y.S., Shirkhedkar A.A. , Impurity profile: Significance in Active Pharmaceutical Ingredient , Department of Pharmaceutical Chemistry, R. C. Patel College of Pharmacy, Shirpur, Dist: Dhule - 425 405 (MS), India. (2007), 204-208.
Ayre A. , Varpe D., Nayak R. , Vasa N. , impurity profiling of pharmaceuticals, Dr. L. H. Hiranandani College of Pharmacy, Ulhasnagar, Maharashtra, India. (2011),:365-378
Gupta R. , Dr. S. Jain, Gupta A. , a review on the impurity profiling in pharmaceuticals, Department of Pharmaceutical Quality Assurance, M.M College of Pharmacy, Maharishi Markandaeshwar University Mullana-133207 (Ambala), Haryana, India.(2014),:301-310.
Drug characterization of impurity,manual for use by national law enforcement authorities and drug testing laboratories United Nations New York, (2001), 378-392.
Gorog S., Babjak M., andBaloghG..Drug impurity profiling strategies, Talanta 44: 1517-1526 (1997).
Ayre A., Varpe D., Nayak R., Vasa N., Impurity profiling of Pharmaceuticals. Advance Research in Pharmaceutical and Biologicals 2011; 1(2): 76-90.
International Conference on Harmonization (1999) Specifications, Q6A: Test Procedures and Acceptance Criterial for New Drug Substances and New Drug Products. Chemical substances 65 (146):67488. 198-210.
Ahuja S. (1998) Impurities Evaluation of Pharmaceuticals. Marcel Dekker, New York, p. 130-142.
Gorog S.Identification and Determination of Impurities in Drugs, (2000) Elsevier Science Publishing Company, Amsterdam.154.
ICH Topic Q3A (1995) Impurities Testing Guideline: Impurities in New Drug Substances, The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation, (2006) , Unit.105-113.
Farmer S., Anderson P., Burns P. and Velagaleti R. Forced (2002) Degradation of Ibuprofen in Bulk Drugs and Tablets. Pharmaceutical Technology.(2002), 142-148
Bhat P. and Velingkar V. S. (2004) Synthesis and Characterization of Degradation Products in Diclofenac-Na and Clotrimazole. Indian Drugs 40 (7): 396-400.
Volk K. J., Hill S. E., Kerns E. H., Lee M. S. (1997) Profiling degradants of paclitaxel using liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry substructural techniques. J.Chromatogr B. 696(1):
Riley T. N. (1998) Steric aspects of drug action. Pharmacist 23(3): 40-51.
Skoog D.A., Holler F.J., and Crouch S.R., Principles of Instrumental Analysis. Cengage Learning, 2017. 142-157.
Shukla R., Singh K., and Upadhyay S., “A Comprehensive Review on HighPerformance Liquid Chromatography (HPLC),” vol. 27, no. 1, (2023), 312–324.
Dongare M.V.S.,Kohale D.N.B., and Rathod M.S.B., “A Review of Chromatography:Principal,Classification, Application,” Int. J. Humanit. Soc. Sci. Manag., vol. 3, no. 2, 367–373,2023
Food and Drug Administration for Immediate Release Consumer Media (1998) 888- Info- FDA. May 6, 1-8.
Roy J., Mahmud M., Sobhan A., Aktheruzzaman M., Al-Faooque M and Ali E (1994) ,Marketed vitamin B-complex injectables: stability and mutual interaction. Drug Dev Ind Pharm 20(13): 1344-1351.
Conner K. A., Amidon G. L. and Stella V. J. (1986), Chemical Stability of Pharmaceuticals-A Handbook of Pharmacists. New York: John Willey & Sons, 458-460.
Dongare M.V.S., Kohale D.N.B., and Rathod M.S.B., “A Review of Chromatography:Principal,Classification, Application,” Int. J. Humanit. Soc. Sci. Manag., vol. 3, no. 2, (2023) , 367–373,
Aydoğan C., “Recent advances and applications in LC-HRMS for food and plant natural products: a critical review,” Anal. Bioanal. Chem., vol. 412, no. 9, (2020), page no.1973– 1991.
Shah S.R., Patel M.A., Naik M.V., Pradhan P.K., and Upadhyay U.M., “impurity profiling in pharmaceutical analysis : (2012), 3503-3517.
Gupta R,, Dr. Jain S. , Gupta A., A review on the impurity profile of pharmaceuticals ,International journal of drug formulation and research (2012),. 312-322.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Shounak R. Mande, Shankar S. Yelmame, Laxmikant B. Borse Laxmikant B. Borse
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.